ObjectivesTo evaluate the performance of direct-to-consumer pulse oximeters under clinical conditions, with arterial blood gas measurement (SaO2) as reference standard.DesignCross-sectional, validation study.SettingIntensive care.ParticipantsAdult patients requiring SaO2-monitoring.InterventionsThe studied oximeters are top-selling in Europe/USA (AFAC FS10D, AGPTEK FS10C, ANAPULSE ANP 100, Cocobear, Contec CMS50D1, HYLOGY MD-H37, Mommed YM101, PRCMISEMED F4PRO, PULOX PO-200 and Zacurate Pro Series 500 DL). Directly after collection of a SaO2 blood sample, we obtained pulse oximeter readings (SpO2). SpO2-readings were performed in rotating order, blinded for SaO2 and completed <10 min after blood sample collection.Outcome measuresBias (SpO2–SaO2) mean, root mean square difference (ARMS), mean absolute error (MAE) and accuracy in identifying hypoxaemia (SaO2 ≤90%). As a clinical index test, we included a hospital-grade SpO2-monitor (Philips).ResultsIn 35 consecutive patients, we obtained 2258 SpO2-readings and 234 SaO2-samples. Mean bias ranged from −0.6 to −4.8. None of the pulse oximeters met ARMS ≤3%, the requirement set by International Organisation for Standardisation (ISO)-standards and required for Food and Drug Administration (FDA) 501(k)-clearance. The MAE ranged from 2.3 to 5.1, and five out of ten pulse oximeters met the requirement of ≤3%. For hypoxaemia, negative predictive values were 98%–99%. Positive predictive values ranged from 11% to 30%. Highest accuracy (95% CI) was found for Contec CMS50D1; 91% (86–94) and Zacurate Pro Series 500 DL; 90% (85–94). The hospital-grade SpO2-monitor had an ARMS of 3.0% and MAE of 1.9, and an accuracy of 95% (91%–97%).ConclusionTop-selling, direct-to-consumer pulse oximeters can accurately rule out hypoxaemia, but do not meet ISO-standards required for FDA-clearance
Background: The demand for pulse oximeters is high in the current COVID-19 pandemic. Despite their popularity, clinical studies to evaluate the reliability in obtaining information on a patient's oxygenation status, are lacking. Aim: To evaluate the performance of pulse oximeters under clinical conditions, with arterial blood gas measurement (SaO2) as reference standard. Methods: We studied the accuracy of ten top-selling pulse oximeters in Europe and the USA in an intensive care population at the Flevoziekenhuis in Almere, the Netherlands. The studied pulse oximeters were: AFAC FS10D, AGPTEK FS10C, ANAPULSE ANP 100, Cocobear, Contec CMS50D1, HYLOGY MD-H37, Mommed YM101, PRCMISEMED F4PRO, PULOX PO-200, and Zacurate Pro Series 500DL. Adult patients in whom an SaO2 measurement was obtained as part of routine care were asked for inclusion. Directly after obtaining the SaO2 blood sample we obtained the pulse oximeter readings (SpO2) of the investigational devices, in random order. Outcomes were bias (SpO2-SaO2) mean, root mean square difference (ARMS), mean absolute error (MAE), and accuracy in identifying hypoxemia (SaO2<=90%). As a clinical index test, we included a hospital-grade SpO2-monitor. Results: In 35 consecutive patients we obtained 2,258 SpO2-readings and 234 SaO2-samples. Mean bias ranged from -0.6 to -4.8. None of the pulse oximeters had an ARMS<=3%, the requirement set by ISO-standards and required for FDA 501(k) clearance. The MAE ranged from 2.3 to 5.1, and 5 out of 10 pulse oximeters met the requirements of ≤3%. For hypoxemia, negative predictive values were 98-99%. Positive predictive values ranged from 11-30%. Highest accuracy (95%CI) were found for Contec CMS50D1; 91% (86-94) and Zacurate Pro Series 500DL; 90% (85-94). The hospital-grade SpO2-monitor had an ARMS of 3.0 and MAE of 1.9, and an accuracy of 95% (91-97%). Conclusion: Direct-to-consumer pulse oximeters do not meet ISO-standards required for FDA-clearance, but can accurately rule out hypoxemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.